Research Updates Definition of High-Risk Multiple Myeloma

A new study suggests that multiple myeloma patients who relapse within 36 months of initial treatment, rather than the previous 18-month benchmark, should be considered high-risk. This redefinition is based on a multicenter analysis and aims to improve patient stratification. The research also indicates that T-cell–redirecting therapy shows promise for these patients, offering higher response rates and improved survival.